An injection of Avastin stopped blood-vessel ... A Genentech spokesman said there's limited safety information about uses of Avastin in treating eye diseases. "We don't support or promote the ...

As Avastin needs to be removed from its original vials and introduced into single-use syringes suitable for injection into the eye, Novartis and Roche have long argued that the repackaging ...

On a macro basis, in the first quarter of 2025, the overall size of the branded anti-VEGF category contracted due to an increase in the usage of low-cost off-label repackaged Avastin, likely ...

Learning from our Phase 2, supplemental injections are only permitted if a ... robust than those achieved in the aflibercept control eyes at this time point. A subset of unsupplemented patients ...

Sales in the Pharmaceuticals Division were up 8% in the first quarter to CHF 11.9 billion, owing to strong growth in demand for key drugs like Phesgo (breast cancer), Vabysmo (severe eye diseases ...

Avastin needs to be diluted and repackaged before it can be used in the eye, with dosing every four to six weeks, and is much less expensive. That hasn’t stopped the branded wet AMD drugs from ...

The introduction of the first-generation anti-VEGF drugs—Macugen (pegaptanib), Eylea (aflibercept), Lucentis (ranibizumab), and Avastin (bevacizumab)—has since been followed by longer-lasting agents ...

Worldwide, age-related macular degeneration (AMD) is the leading cause of severe vision loss in people aged 50 or older. Neovascular AMD is an advanced form of the condition, also known as “exudative ...

A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring ...

Pharmaceutical company AvKare has issued a voluntary recall on several of its over-the-counter products for dry and irritated eyes, citing regulatory "deviations" identified during an audit by the ...